On Demand 2026 Monday General Sessions

This course contains the following sessions from Monday's program:

  • Plenary: The Food Allergy GRADE Practice Parameter
  • New Horizons for Angioedema: From First Presentation to Long-Term Control
  • Staying on the Cutting Edge of Drug Allergy Diagnostics
  • The Difficult to Control Asthma Practice Parameter - Cutting Edge Care for Practice
  • Precision Immunology: Practical Tools for the Diagnosis and Management of Monogenic Disorders of Immunity
  • The Power of Your Voice: Practical Advocacy for the Next Generation of Allergists

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Describe key evidence-based recommendations from the updated Food Allergy Practice Parameter regarding the risk factors for development of IgE mediated food allergy.
  • Interpret the GRADE methodology used in developing the Food Allergy Practice Parameter and incorporate its evidence-based recommendations into standardizing oral food challenge and determining individual threshold for food allergy reactions.
  • Apply guideline-based recommendations for the management of eosinophilic esophagitis, and where current management options fall in the paradigm of treatment.
  • Identify clinical features that distinguish histaminergic angioedema vs. bradykinin-mediated angioedema. Outline the appropriate diagnostic evaluation for angioedema, including HAE with normal C1 inhibitor.
  • Describe the epidemiology of HAE with normal C1 inhibitor and appropriate management strategies.
  • Compare current HAE abortive and prophylaxis options and emerging therapies and their mechanisms of action.
  • Gain knowledge on recent RCTs in drug allergy evaluations.
  • Assess new information from the Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (DACAT) trial.
  • Recognize current tools available for diagnostic testing and risk stratification including tools in the ACAAI Penicillin Toolkit and drug allergy toolbox.
  • Recognize the importance of resources used to construct the updated parameter.
  • Review key recommendations regarding anti-inflammatory relievers and biologics.
  • Evaluate and select appropriate practice parameters to manage severe or difficult to treat asthma.
  • Analyze immunologic and non-immunologic features frequently seen in patients with monogenic disorders of immunity and how a genetic diagnosis can lead to precision therapies.
  • Recognize the basics of genetic sequence nomenclature and develop a framework for evaluating variants of uncertain significance that are frequently encountered when ordering genetic testing.
  • Identify new and emerging diagnostic tests that can help guide treatment in patients with features of immune deficiency and/or dysregulation.
  • Analyze how federal healthcare policies influence allergy and immunology practice and identify opportunities to participate in national-level advocacy efforts.
  • Evaluate local healthcare policies that affect allergy care and implement strategies to monitor and address policy issues within one’s own community.
  • Develop effective collaborations with patient advocacy organizations to enhance community education, support patient needs, and strengthen allergy and immunology care delivery. Apply evidence-based communication strategies to create impactful social media messaging that supports patient education and counters
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary

Available credit: 
  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 7.75 CBRN
Course opens: 
11/24/2026
Course expires: 
12/31/2027
Rating: 
0

Kristin C. Sokol, MD, MS, MPH, FACAAI
Derek K. Chu, MD, PhD
Aikaterini Anagnostou, MD, MSc, PhD, FACAAI
Jay A. Lieberman, MD, FACAAI
Alissa B McInerney, MD, FACAAI
Aleena Banerji, MD, FACAAI
Karen S. Hsu Blatman, MD, FACAAI
Marc A. Riedl, MD, MS
David A. Khan, MD, FACAAI
David C. Mari, DO
Aiwei Yan, MD
Allison C. Ramsey, MD, FACAAI
Kimberly G. Blumenthal, MD, MSc, FACAAI
Cosby A. Stone, Jr., MD, MPH
Sharmilee M. Nyenhuis, MD
Matthew A. Rank, MD, FACAAI
Leonard B. Bacharier, MD, FACAAI
Niraj Patel, MD, MS
Jonathan S. Tam, MD, FACAAI
Nikita Raje, MD, FACAAI
Ivan Chinn, MD
Roshini S. Abraham, PhD
Marissa A. Love, MD, FACAAI
Kylie N. Jungles, MD
Travis A. Miller, MD, FACAAI
Lynda G Mitchell, MA, CAE
Farah N. Khan, MD, FACAAI, FAAAAI, FAAP

Available Credit

  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 7.75 CBRN
Please login or create an account to take this course.